| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
6,220,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Lantern Pharma is a clinical stage biotechnology company. Co.'s drug candidates are: LP-100, which exploits cancer cells' deficiency in DNA repair mechanisms; LP-300, which is a cysteine-modifying molecular entity that works to modulate multiple cellular pathways simultaneously and is a potential combination agent for targeted indications in non-small cell lung cancer; LP-184, which is a small molecule that preferentially damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways; and LP-284, which has anti-tumor activities in a variety of hematological cancers including lymphoma, multiple myeloma, and leukemia.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
288,000 |
696,474 |
696,474 |
1,409,364 |
| Total Sell Value |
$1,352,588 |
$2,847,250 |
$2,847,250 |
$5,994,278 |
| Total People Sold |
2 |
2 |
2 |
2 |
| Total Sell Transactions |
6 |
10 |
10 |
14 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Bp Directors, Lp |
10% Owner |
– – • |
2024-02-29 |
4 |
S |
$4.87 |
$95,954 |
I/I |
(19,703) |
137,832 |
|
- |
|
| Bios Advisors Gp, Llc |
10% Owner |
– – • |
2024-02-29 |
4 |
S |
$4.87 |
$95,954 |
I/I |
(19,703) |
137,832 |
|
- |
|
| Bp Directors, Lp |
10% Owner |
– – • |
2024-02-28 |
4 |
S |
$4.85 |
$360,340 |
I/I |
(74,297) |
142,017 |
|
- |
|
| Bios Advisors Gp, Llc |
10% Owner |
– – • |
2024-02-28 |
4 |
S |
$4.85 |
$360,340 |
I/I |
(74,297) |
142,017 |
|
- |
|
| Bp Directors, Lp |
10% Owner |
– – • |
2024-02-27 |
4 |
S |
$4.40 |
$220,000 |
I/I |
(50,000) |
157,797 |
|
- |
|
| Bios Advisors Gp, Llc |
10% Owner |
– – • |
2024-02-27 |
4 |
S |
$4.40 |
$220,000 |
I/I |
(50,000) |
157,797 |
|
- |
|
| Bp Directors, Lp |
10% Owner |
– – • |
2024-01-17 |
4 |
S |
$4.20 |
$247,334 |
I/I |
(58,889) |
168,417 |
|
- |
|
| Bp Directors, Lp |
10% Owner |
– – • |
2024-01-17 |
4 |
OE |
$3.13 |
$247,336 |
I/I |
79,021 |
180,938 |
|
- |
|
| Bios Advisors Gp, Llc |
10% Owner |
– – • |
2024-01-17 |
4 |
S |
$4.20 |
$247,334 |
I/I |
(58,889) |
168,417 |
|
- |
|
| Bios Advisors Gp, Llc |
10% Owner |
– – • |
2024-01-17 |
4 |
OE |
$3.13 |
$247,336 |
I/I |
79,021 |
180,938 |
|
- |
|
| Bios Advisors Gp, Llc |
10% Owner |
– – • |
2023-11-29 |
4 |
S |
$3.44 |
$499,997 |
I/I |
(145,348) |
371,950 |
|
- |
|
| Bp Directors, Lp |
10% Owner |
– – • |
2023-11-29 |
4 |
S |
$3.44 |
$499,997 |
I/I |
(145,348) |
371,950 |
|
- |
|
| Bios Advisors Gp, Llc |
10% Owner |
– – • |
2022-11-08 |
4 |
S |
$4.40 |
$1,540,000 |
I/I |
(350,000) |
164,137 |
|
- |
|
| Bp Directors, Lp |
10% Owner |
– – • |
2022-11-08 |
4 |
S |
$4.40 |
$1,540,000 |
I/I |
(350,000) |
164,137 |
|
- |
|
| Bios Advisors Gp, Llc |
10% Owner |
– – • |
2022-09-02 |
4 |
S |
$5.20 |
$33,514 |
I/I |
(6,445) |
26,093 |
|
- |
|
| Bios Advisors Gp, Llc |
10% Owner |
– – • |
2022-09-02 |
4 |
OE |
$1.03 |
$33,514 |
I/I |
32,538 |
27,328 |
|
- |
|
| Bp Directors, Lp |
10% Owner |
– – • |
2022-09-02 |
4 |
S |
$5.20 |
$33,514 |
I/I |
(6,445) |
26,093 |
|
- |
|
| Bp Directors, Lp |
10% Owner |
– – • |
2022-09-02 |
4 |
OE |
$1.03 |
$33,514 |
I/I |
32,538 |
27,328 |
|
- |
|
| Bios Fund I Qp, Lp |
10% Owner |
– – • |
2022-03-17 |
4 |
OE |
$110,636.00 |
$2,147,483,647 |
I/I |
95,779 |
329,904 |
|
- |
|
| Soderstrom Carl D |
10% Owner |
– – • |
2020-06-15 |
4 |
A |
$0.00 |
$0 |
I/I |
465,837 |
131,697 |
|
- |
|
| Bp Directors, Lp |
10% Owner |
– – • |
2020-06-15 |
4 |
A |
$0.00 |
$0 |
I/I |
1,456,648 |
89,522 |
|
- |
|
| Bios Advisors Gp, Llc |
10% Owner |
– – • |
2020-06-15 |
4 |
A |
$0.00 |
$0 |
I/I |
1,456,648 |
89,522 |
|
- |
|
| Keyser D Jeffrey |
Director |
– • – |
2020-06-15 |
4 |
A |
$0.00 |
$0 |
D/D |
31,927 |
41,927 |
|
- |
|
| Keyser D Jeffrey |
Director |
– • – |
2020-06-11 |
4 |
B |
$15.00 |
$150,000 |
D/D |
10,000 |
10,000 |
2.39 |
- |
|
| Bios Advisors Gp, Llc |
10% Owner |
– – • |
2020-06-10 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
304,498 |
|
- |
|
29 Records found
|
|
Page 1 of 2 |
|
|
